The Australian Breast Cancer drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Breast cancer is the most common cancer in women in Australia (apart from non-melanoma skin cancer) and the second most common cancer to cause death in women, after lung cancer. In Australia, the overall five-year survival rate for breast cancer in females is 91%. If the cancer is limited to the breast, 96% of patients will be alive five years after diagnosis; this figure excludes those who die from other diseases. If cancer has spread to the regional lymph nodes, five-year relative survival drops to 80%. In 2016, 17,354 women and 138 men were diagnosed with breast cancer in Australia. The risk of being diagnosed with breast cancer by age 85 is 1 in 8 for women and 1 in 651 for men.
The rising prevalence of breast cancer about factors such as prolonged exposure to endogenous oestrogens, early menarche, late age at first childbirth, and late menopause will be a high impact rendering factor for the industry growth. The increasing rate of alcohol consumption in women, rising use of hormone replacement therapy (HRT), and oral birth control pills resulting in increased levels of oestrogen will boost the business size over the forecast period. Growing awareness regarding breast cancer, rising shift towards adoption of western lifestyle, short breast-feeding timeframe, and rising prevalence of obesity in women after menopause will drive the industry size.